Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $10.47, but opened at $10.88. Gyre Therapeutics shares last traded at $11.13, with a volume of 29,084 shares traded.
Gyre Therapeutics Trading Up 10.0 %
The company has a fifty day simple moving average of $13.29 and a two-hundred day simple moving average of $12.66.
Hedge Funds Weigh In On Gyre Therapeutics
Several institutional investors have recently modified their holdings of GYRE. Geode Capital Management LLC increased its position in shares of Gyre Therapeutics by 16.9% in the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock valued at $3,808,000 after buying an additional 43,840 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock valued at $1,425,000 after acquiring an additional 90,557 shares during the period. State Street Corp increased its holdings in shares of Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after acquiring an additional 8,412 shares in the last quarter. Advantage Alpha Capital Partners LP bought a new stake in Gyre Therapeutics during the 3rd quarter worth approximately $334,000. Finally, WINTON GROUP Ltd acquired a new stake in Gyre Therapeutics during the 2nd quarter worth approximately $220,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
See Also
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
